Silver sulfadiazine cream (SSD) has been used successfully in the management of burn wound sepsis. Silver deposition has been found in the skin, gingiva, cornea, liver, and kidney of patients treated with this cream, causing argyria, ocular injury, leukopenia, and toxicity in kidney, liver, and neurologic tissues. Monitoring concentrations of silver in blood and urine of patients receiving this treatment has become necessary, but sensitive and The development of sepsis after thermal injury is the major cause of high mortality in burn patients. Various treatments have been used to prevent and control sepsis (1,2), but none is more successful than the topical use of silver sulfadiazine (SSD) cream (3-5), although this treatment is not without adverse effects. Argyria in gingiva and cheek tissues (6), nephrotic syndrome (7), and leukopema (8) have all been reported in severely burned patients being treated with SSD cream. Silver toxicity is well known among workers in factories manufacturing silver nitrate and silver oxide (9), in the photochernical industry (10), and in people taking antismoking chewing gum containing silver acetate (11, 12) and was reported in a patient receiving arthroplasty (17) found only moderate increases in the concentration of silver in plasma of burn patients. Given the potential for toxicity from silver, we consider it important to monitor routinely the concentrations of silver in plasma and urine in patients undergoing treatment with SSD cream. We have developed an easy method based on electrothermal atomic absorption spectrometry but without use of the Zeeman background correction and platform recommended elsewhere (18,19). To alleviate the serum matrix effect, we used NH4NO3 as the matrix modifier and assayed standards supplemented with bovine serum albumin (BSA), Na, K, Cl-, and bicarbonate. We also investigated the effects of matrix modifiers such as nickel and palladium salts.
The development of sepsis after thermal injury is the major cause of high mortality in burn patients. Various treatments have been used to prevent and control sepsis (1,2), but none is more successful than the topical use of silver sulfadiazine (SSD) cream (3-5), although this treatment is not without adverse effects. Argyria in gingiva and cheek tissues (6), nephrotic syndrome (7) , and leukopema (8) have all been reported in severely burned patients being treated with SSD cream. Silver toxicity is well known among workers in factories manufacturing silver nitrate and silver oxide (9) , in the photochernical industry (10), and in people taking antismoking chewing gum containing silver acetate (11, 12) and was reported in a patient receiving arthroplasty cement containing silver (13) . In vitro studies have also shown that silver causes cellular (14, 15) and subcellular (16) toxicity. The possible absorption of silver in burn patients treated with SSD cream and its consequent toxic effect are thus a cause of concern. Published data on absorption of silver through topical use are scarce and controversial. Fox et al. (15) reported that no significant absorption was detected. Boosalis et al. (17) found only moderate increases in the concentration of silver in plasma of burn patients. Given the potential for toxicity from silver, we consider it important to monitor routinely the concentrations of silver in plasma and urine in patients undergoing treatment with SSD cream. We have developed an easy method based on electrothermal atomic absorption spectrometry but without use of the Zeeman background correction and platform recommended elsewhere (18, 19) . To alleviate the serum matrix effect, we used NH4NO3 as the matrix modifier and assayed standards supplemented with bovine serum albumin (BSA), Na, K, Cl-, and bicarbonate. We also investigated the effects of matrix modifiers such as nickel and palladium salts.
MaterIals and Methods

Apparatus:
A Model 3030 atomic absorption spectrophotometer (Perkin-Elmer Corp.,
Norwalk,
CT),
equipped with deuterium lamp background correction and an attached Model HGA-400 graphite furnace unit, was used in this study. The silver hollow-cathode lamp (Photron Pty., Ltd., Dandenong, Victoria, Australia) with a wavelength of 328.1 urn and a high-density graphite carbon tube (Perkin-Elmer) without platform were used in the assay.
Reagents:
Water purified in a high-grade Milli-Ro De-ionizer system (Millipore, Melbourne, Australia) with resistance >14 MCi was used to prepare all reagents. A 0.5 mJJL aqueous solution of Triton X-100 (iso-octylphenoxypolyethoxy ethanol), containing 40 g of NH4NO3 per liter as the matrix modifier, was used for the final dilution of all samples, including standards, controls, and patients' specimens. Aqueous solutions containing 2 g of nickel per liter, prepared from Ni(N03)2 -6H20, and 4 g of palladium per liter, prepared from Pd(N03)2 2H20, were also tried as alternative matrix modifiers. All chemicals were of analytical grade (BDH Chemicals, Sydney, Australia). High-purity nitrogen was used as purging gas. A solution containing 60 g of BSA Control specimens: Two poo1s of sera containing -12 and -40 pg of silver per liter were used as controls. They were prepared by diluting serum of high silver content with normal human serum to the desired ranges. The pooled sera were mixed, filtered, aliquotted (0.5 mL) into capped small plastic sample cups, and stored at -70 #{176}C. They were used at the beginning of each run to standardize the instrument and also during the run to assess possible drift. These control specimens were stable for at least 12 months under these conditions.
Specimen preparation:
The blank (BSA matrix solution), standards, control, and patients' plasma and urine specimens were all diluted fivefold with the Triton X-100 solution before assay. Urine samples were well mixed (without centrifugation) before sampling. Tissue specimens were first rinsed with 8.5 g/L NaC1 solution to remove possible contamination of blood and were then blot-dried with filter paper. The wet tissue (0.5 g) was roughly diced and then dissolved in 2 mL of 10 mol/L HNO3 in a 15-mL glass tube by heating the tube at 120 #{176}C for 15 mm. After cooling to room temperature, the contents were diluted to 10 mL with water. These tissue preparations were also diluted fivefold with the Triton X-100 solution before assay. Factors for dilutions were included in the final calculation.
Analytical procedure: For this assay, we used the alternative slit (0.7 pni) on the instrument and a 20-pL sample volume. Samples with silver concentrations >50 pg/L were diluted to below that concentration before assay. Automatically integrated peak areas were used for calculation of results. To optimize the procedure, we evaluated ashing temperatures between 300 and 1200#{176}C, and atomization temperatures between 1100 and 2500 #{176}C, using pooled human serum with a silver content of 13.6 pg/L.
Results
The effect of ashing temperature, with NH4NO3 as modifier, on the silver yield is shown in Figure 1 . The ashing was incomplete at temperatures <600 #{176}C, and the effect of the matrix background was noticeable.
Ashing appeared complete when the ashing temperature was between 650 and 750 #{176}C; when >800#{176}C, silver loss was noticeable. We chose an ashing temperature of 700#{176}C for this study. When nickel was included as matrix modifier, a higher temperature of 900 #{176}C for ashing could be achieved. However, this yielded no greater sensitivity and gave no improvement in the recovery, but led to formation of precipitates during the preparation of plasma specimens, so we did not use this approach. An attempt at using palladium nitrate as a modifier was abandoned due to its high silver content.
The survey on the effect of atomization temperature on silver recovery showed that little atomization oc- 
Assay Precision Assessment
The within-run and between-run precision studies were performed with pooled plasma specimens containing silver at selected concentrations. The within-run precision was determind at three concentrations: 5, 13.5, and 42 pgfL; between-run precision was determined at two concentrations: 13. Temperature (#{176}C)
Fig. 2. Effect of atomizationtemperatureon silverdetermination
Low percentage yield at <2000#{176}C indIcates Incomplete atomization
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HeatIng Program are shown in Table 2 . The between-run imprecisions were slightly greater than the within-run variations; nevertheless, all were within our acceptable value for a CV of 5%. (Table 3) .
Accuracy and Analytical Recovery Studies
Recovery studies were done by assaying a patient's serum with known amounts of silver added. The increase in values was compared with the quantities added. Recoveries were satisfactory and ranged between 94% and 99%, with a mean of 97.5% (Table 4) . area (population >3 X 10), whose occupations were not related to silver manufacturing and who had no history of silver medication, were analyzed for silver. Silver concentrations were all <1 pg/L. Analysis of 24-h urine collections from the same individuals showed that urinary excretion of silver was <2 pg/day, except for two cases with values of 2.3 and 2.1 pg/day. These findings are lower than those reported by DiVincenzo et al. (20) , who showed that normal human serum and urine contained silver concentrations <5 pg/L.
Studies of Plasma and Urine Silver Concentrations in Bum Patients
Blood and urine specimens collected on admission to the hospital served to establish baselines for silver content. After the application of SSD cream, blood specimens were collected for silver assay at 6 h, and on days 1,2,3,5,7,10, and 14, and then biweekly until the patients were discharged.
Urine specimens (24 h) were collected on days 1, 2, 5, and 8 for silver determination.
Silver content in the blood increased quickly after application of SSD cream (Figure 4) . After 6 h, all patients who suffered from burns of >5% of total body surface area showed a marked increase in silver concentration, to as much as 69 pg/L. Peak concentrations of silver in plasma, depending on the surface area burned,
CV,
were reached in 10±3 (mean ± SD) days, ranging from seven to 17 days; the maximum plasma concentration of Boosalis et al. (17) used flame atomic absorption spectrophotometry, which is less sensitive than the flameless thermal furnace type we used.
Urinary excretion of silver is summarized for nine patients in Figure 5 , which shows that absorbed silver is readily excreted in the urine. After only 24 h of treatment with SSD cream, mean urinary silver excretion was considerably increased toll (SD 9) pg/day, more than fivefold that of normal subjects. Peak concentrations of silver in urine were reached in 6.7 (SD 2.1) days (range five to 12 days). The highest value found, 558 pg/day in one patient, was less than the 1100 pg/day reported by Boosalis et al. (17) . Unlike their group of patients, no one we studied had >35% of total body surface burned.
Silver Deposition in Tissues
One patient, age 81 years, had 25% of the total body surface burned and died of renal failure after eight days of treatment with SSD cream. Postmortem studies of silver content in the liver, kidney, and cornea showed that silver deposition was quite high in these tissues ( Table 5 ). The corneal tissue had the highest concentration, followed by the liver and the kidney, with 970, 14, atomic absorption spectrophotometry was used for silver analysis in human blood (18). The method involved an instrument equipped with Zeeman background correction and techniques such as standard additions and the use of a platform in the carbon tube. We found that by using a standard electrothermal atomic absorption spectrometer equipped with deuterium background correction, we achieved enough sensitivity and did not require standard additions or a platform for measuring silver in blood, urine, and tissues. The serum matrix effect was overcome by the presence of NH4NO3 and was balanced by using standards supplemented with BSA, Na, K, Cl, and bicarbonate. The use of nickel or palladium as matrix modifiers was not necessary, because these gave no improvement in ana-CLINICALCHEMISTRY,Vol. 37, No. 10, 1991 1687 lytical recovery. In addition, the commercial product of palladium compound was found to contain silver in a high enough concentration to be unsuitable for the assay.
The method presented here is simple and easy to operate, and the sensitivity and precision remain suitable for routine use. Silver is readily absorbed through topical application.
As early as 6 h post-application, silver concentrations in plasma reached >50-fold the normal concentration.
Plateau values were reached in three to four days. Although silver is cleared through the urine, it is also deposited in liver, kidney, and corneal tissue, as shown in one patient who died eight days after admission. The physiological and pathological effects of silver deposition in a larger group of patients are being documented and will be reported separately.
